Global Information
회사소개 | 문의 | 비교리스트

중증하지허혈 : 파이프라인 리뷰

Critical Limb Ischemia - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 219779
페이지 정보 영문 153 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


중증하지허혈 : 파이프라인 리뷰 Critical Limb Ischemia - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 153 Pages

중증하지허혈은 말초동맥질환(PAD) 중 가장 심각한 증상입니다. 죽상동맥경화증에 관련된 만성적인 염증 과정이 원인입니다. 주요 증상에는 다리·발가락의 통증 및 저림, 진무름,피부 감염증 등이 있으며, 모두 발증 후에는 치료가 불가능합니다. 이 질환의 치료 목적은 관상동맥에 대한 위험인자 경감(금연, 콜레스테롤 경감 등), 통증 완화, 궤양 치유, 절단 수술 회피, 삶의 질(QoL) 개선, 생존률 향상 등입니다.

세계 각국에서의 중증하지허혈(CLI) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 각 단계별 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

중증하지허혈 - 개요

중증하지허혈 - 치료제 개발

  • 파이프라인 개요
  • 기업별 파이프라인 동향
  • 대학·연구기관별 파이프라인 동향
  • 기업에서 개발중인 제품
  • 대학·연구기관에서 개발중인 제품

중증하지허혈 - 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

중증하지허혈 치료제 개발에 참여하고 있는 기업

  • AnGes MG Inc
  • apceth Biopharma GmbH
  • Athersys Inc
  • BiogenCell Ltd
  • Caladrius Biosciences Inc
  • Cynata Therapeutics Ltd
  • Hemostemix Ltd
  • Histocell SL
  • ID Pharma Co Ltd
  • Integene International Holdings LLC
  • Juventas Therapeutics Inc
  • Kasiak Research Pvt Ltd
  • Kowa Company Ltd
  • Neurofx Inc
  • Pharmicell Co Ltd
  • Pluristem Therapeutics Inc
  • ReNeuron Group Plc
  • Symic Biomedical Inc
  • TikoMed AB
  • U.S. Stem Cell Inc
  • Vericel Corp
  • VESSL Therapeutics Ltd
  • ViroMed Co Ltd

약제 개요

중증하지허혈 - 휴지중인 프로젝트

중증하지허혈 - 개발이 중지된 제품

중증하지허혈 - 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 17.06.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Critical Limb Ischemia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Critical Limb Ischemia - Pipeline by Anaeropharma Science Inc, H1 2020
  • Critical Limb Ischemia - Pipeline by Antidote Therapeutics Inc, H1 2020
  • Critical Limb Ischemia - Pipeline by apceth Biopharma GmbH, H1 2020
  • Critical Limb Ischemia - Pipeline by Athersys Inc, H1 2020
  • Critical Limb Ischemia - Pipeline by BiogenCell Ltd, H1 2020
  • Critical Limb Ischemia - Pipeline by Biotech Holdings, H1 2020
  • Critical Limb Ischemia - Pipeline by Caladrius Biosciences Inc, H1 2020
  • Critical Limb Ischemia - Pipeline by Constant Therapeutics LLC, H1 2020
  • Critical Limb Ischemia - Pipeline by Cynata Therapeutics Ltd, H1 2020
  • Critical Limb Ischemia - Pipeline by Gurus BioPharm, H1 2020
  • Critical Limb Ischemia - Pipeline by Helixmith Co Ltd, H1 2020
  • Critical Limb Ischemia - Pipeline by Hemostemix Inc, H1 2020
  • Critical Limb Ischemia - Pipeline by ID Pharma Co Ltd, H1 2020
  • Critical Limb Ischemia - Pipeline by Juventas Therapeutics Inc, H1 2020
  • Critical Limb Ischemia - Pipeline by Kang Stem Biotech Co Ltd, H1 2020
  • Critical Limb Ischemia - Pipeline by Libella Gene Therapeutics, H1 2020
  • Critical Limb Ischemia - Pipeline by LifeCells LLC, H1 2020
  • Critical Limb Ischemia - Pipeline by Nissan Chemical Corp, H1 2020
  • Critical Limb Ischemia - Pipeline by Pharmicell Co Ltd, H1 2020
  • Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc, H1 2020
  • Critical Limb Ischemia - Pipeline by ReNeuron Group Plc, H1 2020
  • Critical Limb Ischemia - Pipeline by Reven Pharmaceuticals Inc, H1 2020
  • Critical Limb Ischemia - Pipeline by Rexgenero Ltd, H1 2020
  • Critical Limb Ischemia - Pipeline by TaiGen Biotechnology Co Ltd, H1 2020
  • Critical Limb Ischemia - Pipeline by Taiwan Bio Therapeutics Co Ltd, H1 2020
  • Critical Limb Ischemia - Pipeline by Theratome Bio Inc, H1 2020
  • Critical Limb Ischemia - Pipeline by U.S. Stem Cell Inc, H1 2020
  • Critical Limb Ischemia - Pipeline by VESSL Therapeutics Ltd, H1 2020
  • Critical Limb Ischemia - Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H1 2020
  • Critical Limb Ischemia - Dormant Projects, H1 2020
  • Critical Limb Ischemia - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Critical Limb Ischemia - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Critical Limb Ischemia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H1 2020, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.

Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 13, 3, 2 and 8 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Critical Limb Ischemia - Overview
  • Critical Limb Ischemia - Therapeutics Development
  • Critical Limb Ischemia - Therapeutics Assessment
  • Critical Limb Ischemia - Companies Involved in Therapeutics Development
  • Critical Limb Ischemia - Drug Profiles
  • Critical Limb Ischemia - Dormant Projects
  • Critical Limb Ischemia - Discontinued Products
  • Critical Limb Ischemia - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q